Blog
RSS FeedPosted by Michael Wonder on 04 Sep 2023
Working with Te Whatu Ora to enable better access to vaccines
4 September 2023 - This year, many New Zealanders received their vaccinations at pharmacies close to their homes or workplaces. ...
Posted by Michael Wonder on 04 Sep 2023
PHARMAC widens access to treatment for life-long bleeding disorder, severe haemophilia A
4 September 2023 - PHARMAC has confirmed it is widening access to emicizumab (Hemlibra) for the treatment of people with severe ...
Posted by Michael Wonder on 04 Sep 2023
ACT calls for "productivity focus" for PHARMAC
3 September 2023 - The policy was discussed on Q+A with Jack Tame by new candidate Todd Stephenson, who has ...
Posted by Michael Wonder on 04 Sep 2023
PHARMAC funds first treatment for primary progressive multiple sclerosis
4 September 2023 - PHARMAC has confirmed it is widening access to ocrelizumab (Ocrevus) as the first funded treatment for ...
Posted by Michael Wonder on 31 Aug 2023
New Zealand Pharmaceutical Schedule - 1 September 2023
1 September 2023 - The September 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 29 Aug 2023
PHARMAC taking action to ensure supply of type 2 diabetes medicine amid worldwide shortage
29 August 2023 - PHARMAC is taking steps to ensure people with type 2 diabetes who take dulaglutide (branded as Trulicity) ...
Posted by Michael Wonder on 28 Aug 2023
MyLifeMatters calls for new medicines, urgent PHARMAC investment
28 August 2023 - The MyLifeMatters campaign says New Zealanders’ ability to get new and breakthrough medicines lags behind other ...
Posted by Michael Wonder on 27 Aug 2023
PHARMAC announcement of more blood cancer medicines welcomed
27 August 2023 - Myeloma New Zealand is welcoming Pharmac's announcement of more blood cancer medicines, but says the country is ...
Posted by Michael Wonder on 24 Aug 2023
PHARMAC seeking bids from suppliers for multiple myeloma treatments
24 August 2023 - PHARMAC is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the ...
Posted by Michael Wonder on 23 Aug 2023
PHARMAC confirms transition to a trastuzumab biosimilar and widens access to other types of cancer
23 August 2023 - PHARMAC is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin, as a result ...
Posted by Michael Wonder on 22 Aug 2023
Suggestions Nat's cancer drug funding promise has put PHARMAC in a difficult position
22 August 2023 - It's being suggested National's cancer drug funding promise has put PHARMAC in a difficult position. ...
Posted by Michael Wonder on 21 Aug 2023
National to roll back free prescription fees to pay for 13 cancer treatments
21 August 2023 - The National Party wants to bring back the $5 prescription fee for those who can afford ...
Posted by Michael Wonder on 16 Aug 2023
PHARMAC publishes agenda for this week's PTAC meeting
16 August 2023 - Another underwhelming agenda that was only published after agitation on social media. ...
Posted by Michael Wonder on 16 Aug 2023
PHARMAC calls for applications from the suppliers of vaccines that protect against COVID-19
16 August 2023 - PHARMAC is interested to hear from pharmaceutical suppliers who manufacture vaccines that protect against COVID-19 and ...
Posted by Michael Wonder on 15 Aug 2023
PHARMAC indicates interest to fund more oestradiol treatments to relieve supply issue
15 August 2023 - PHARMAC is planning to issue a competitive process for supply of oestradiol transdermal products in New Zealand. ...